I-MAB BIOPHARMA
天 境 生 物

I-MAB

Company Profile

January 2022

Disclaimer

This presentation has been prepared by I-Mab (the "Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed.

This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident," or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized.

By viewing, accessing, or participating in this presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Our Mission

Bring transformational medicines to patients through innovation

Our Vision

We are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology and autoimmune diseases for patients in China and around the world

Our Values

Innovation Integrity Resilience

Transformative Journey Towards a Global Biopharma

Company Highlights: We Differentiate with Global Ambition

Global Innovation

First-in-Class and Best-in-Class Potential

Immuno-Oncology Focus

Three Waves of Innovation

(Monoclonal, Bi-specific, Super Antibodies)



Global Pipeline

Innovative and Advanced

10 clinical and 10 pre-clinical assets

Over 20 clinical trials[1], including 15 Ph 2/Ph 3

Global Business

Over 20 BD transactions

Revenue stream ~$1 billion by 2025

Listings on NASDAQ and soon HKEX

Becoming Global Biopharma

Start-up (2016), **Biotech** (now), **Biopharma** (2024/2025)

Global R&D, Shanghai, San Diego, Maryland, Beijing

Commercialization, GMP manufacturing (Hangzhou)

1. By end of 2022

FIRST-IN-CLASS

BEST-IN-CLASS

- Immuno-Oncology Focused Innovation
- Innovative and Globally Competitive Pipeline
- Value Creation through Global Collaborations
- Fully Integrated Global Biopharma
- Team and Capabilities
- Company Highlights

Immuno-Oncology Focused Innovation

Innovation System: Addressing Oncology Unmet Medical Needs

Poor efficacy of standard of care

Unmet Medical Needs

Novel target
Novel molecule
New modality

Molecular Innovation

Novel trial design
Novel biomarker

Clinical Validation

Innovative Medicines

Value Realization

Evolution of Cancer Treatments

Surgery

In 1881, the first gastric cancer surgery was successfully performed

Radiation Therapy

In 1903, radiation was first used to treat skin cancer

Chemotherapy

In 1949, FDA approved the first chemotherapy drug (nitrogen mustard) for the treatment of Hodgkin's lymphoma

Targeted Therapy

In 1997, FDA approved the first biologic targeted therapy: *Rituximab*

Immunotherapy

In 2011, FDA approved the first immune checkpoint inhibitor: *Ipilimumab*

Source: Literature search, Frost & Sullivan report

Cancer Immunotherapy Market Potential

Global cancer drug market: 2020 vs 2030E



~ USD 150 billion **~ USD 483 billion**

China cancer drug market: 2020 vs 2030E



~ USD 31.3 billion **~ USD 108.4 billion**

Chemotherapy Targeted Therapy Immunotherapy

Source: Literature search, Frost & Sullivan report

Unmet Medical Needs in Oncology

Clinical Response Rate to PD-1/PD-L1 Therapy Less Than 30%

High Response



Hot Tumor

Cold Tumor

NEJM (2017) 377;25:2500

Cutting-Edge Science: Fine-Tuning Immune Network for Cancer

Bi-Specific Antibody

Monoclonal Antibody

"Cold Tumor"



"Hot Tumor"



Immune Network





Tumor Engager

PD-L1, CD47, Claudin 18.2
Claudin 6

Immune Activation

4-1BB, LAG3, TIGIT, IL-7
CD73, C5aR, B7H3, GM-CSF



Novel Molecule

Innovative Therapeutic Antibodies in Three Waves

Tech-enabled "Super Antibody"



Alphabody: *Cell-penetrating antibody*
Probody: *Locally activated antibody*
4-1BB platform: *Bi-specific antibody*
AI Design: *Novel antibody properties*
mRNA: *In vivo synthesized antibody*



Candidates / CMC
IND expected 2022 / 2023

Novel Bi-Specific Antibody



L14B *PD-L1 x 4-1BB*
CD4B *CLDN18.2 x 4-1BB*
L1IF *PD-L1 x IFN*
C64B *CLDN6 x 4-1BB*
CD47 *x partners*

Ph 1, Ph 2 clinical and pre-clinical
2022

Highly Differentiated mAb



Lemzoparlimab *CD47*
Uliledlimab *CD73*
Plonmarlimab *GM-CSF*
Enoblituzumab *B7H3*
TJ210 *C5aR*
Efineptakin alfa *IL-7*

Ph 2, registrational clinical trials
2022

Lemzoparlimab: Differentiation by Design



Novel Molecule

Lemzoparlimab: Novel Underlying Mechanism

Minimal binding to RBC

Unique glyco-epitope



Lemzoparlimab









Lemzoparlimab: Clinical Differentiation

Molecular Differentiation[1]



Clinical Differentiation[1]

- Good safety, no hemolytic anemia
- No priming dose required
- No “sink effect”
- Anti-tumor activity

1. Based on data from multiple clinical trials as of Dec 31, 2021

Uliledlimab: A Global Frontrunner CD73 Antibody with Differentiation

Why Targeting CD73?



Rate-limiting

Antibody vs. Small Molecule



- Inhibition by a non-competitive manner
- Full target occupancy and sustained blockade

AMP levels in primary tumors reaches to **500 μM**

Key Differentiation

Unique intra-dimer binding through a C-terminus epitope



Complete CD73 inhibition without the "hook effect"



Novel Molecule

TJ-CD4B: A Novel Claudin 18.2 and 4-1BB Bi-Specific Antibody

CLDN18.2



4-1BB

Novel tumor-engager

- Stronger than zolbetuximab
- Applicable to a wide range of CLDN18.2 expression tumors

Conditional 4-1BB agonist

- Potent intra-tumor 4-1BB agonism
- CLDN18.2 dependent 4-1BB activation to avoid systemic toxicity

CD4B MOA: Conditional Activation



Safety and Tumor Inhibition



- TJ-CD4B (Claudin 18.2 x 4-1BB) shows better efficacy than combo or mono-therapy
- Mice with complete regression were protected against tumor re-challenge

Novel Molecule

Super Antibodies Enabled by Transformative Technologies

Synthesize antibodies in-vivo with mRNA

Alphavirus RNA genome



Self-amplifying mRNA genome

Local activation at tumor sites

Masked antibody

Active antibody



Tumor-specific protease



Biologics synthesis by AI algorithm



Cell penetration for intracellular target



Novel Molecule

Innovative and Globally Competitive Pipeline

Competitive and Risk-Balanced Global & China Portfolios

Clinical Validation
Clinical differentiation
Safety & preliminary efficacy

Accelerated Clinical Development
Global clinical data
To facilitate clinical development

Global Partnership
License out global rights
Retain greater China rights

Value Creation
Cash inflow before product launch
Global sales sharing

Accumulative Cash Flow of USD 1 Billion by 2025



BLA 2022/2023 onwards

2nd wave	1st wave
Uliledlimab CD73	*Felzartamab CD38*
Enoblituzumab B7H3	*Eftansomatropin*
Efineptakin alfa	*Lemzoparlimab CD47*
	Plonmarlimab GM-CSF
More assets in clinical and pre-clinical stage	*In-licensed products*

Innovative and Advanced Immuno-Oncology Pipeline[1]

Pipeline Assets	Commercial Rights	Indications (combo)	Pre-clinical	Phase I	Phase 2	Phase 3/ Registrational	BLA
Felzartamab TJ202 Differentiated CD38 antibody	Greater China	**Multiple Myeloma** 3L, 2L, other combo positioned for potential 1L			New Combo New Combo	MM 2L	MM 3L
Eftansomatropin Alfa TJ101 Differentiated long-acting GH	China	**Pediatric Growth Hormone De ficiency PGHD**				PGHD	2023/2024
Lemzoparlimab TJC4 Differentiated CD47 antibody	Greater China[2] Global (AbbVie)	**Acute Myeloid Leukemia** (AZA) **Myelodysplastic Syndromes** (AZA) **Non-Hodgkin's Lymphoma** (rituximab) **Solid Tumors** (PD-1)		2 trials 2 trials 2 trials	AML MDS NHL Solid Tumors	2022 2022	
Uliledlimab TJD5 Differentiated CD73 antibody	Global	**Solid Tumors** (PD-1/PD-L1) **Solid Tumors** (new combo)			Solid Tumors Solid Tumors New Combo New Combo		
Plonmarlimab TJM2 GM-CSF antibody	Global	**Cytokine release syndrome**			CRS-COVID19		
Enoblituzumab TJ271 Novel B7-H3 antibody	Greater China	**Solid Tumors** (PD-1) **Solid Tumors** (new combo)			Solid Tumors New Combo		
Efineptakin Alfa TJ107 Novel long-acting IL-7	Greater China	**Solid Tumors** (PD-1) **Glioblastoma** (TMZ)			Solid Tumors GBM		
TJ210 Novel C5aR antibody	Greater China/S. Korea /Global shared	**Solid Tumors** (PD-1) **Solid Tumors** (new combo)		Solid Tumors New Combo			
TJ-L14B Differentiated PD-L1 x 4-1BB	Global shared	**Solid Tumors**		Solid Tumors			
TJ-CD4B Novel Claudin 18.2 x 4-1BB	Greater China /Global shared	**Gastric & Pancreatic Cancers**		Solid Tumors			
Bi-Specific Antibodies & "Super Antibodies"	Global	**Solid Tumors**	Multiple programs: Candidates, CMC pre-clinical stage	Solid Tumors 2022 - 2023			

On-going
Planned

1. As of January 2022; Felzartamab for SLE, Olamkicept for UC and TJX7 are not listed
2. Excluding Taiwan

Novel Trial Design

Our Core Assets

Felzartamab TJ202

- Differentiated CD38 mab in China
- Multiple myeloma (multiple lines)
- Phase 3

Eftansomatropin Alfa *TJ101*

- Differentiated long-acting growth hormone in China
- Pediatric growth hormone deficiency
- Phase 3

Lemzoparlimab *TJC4*

- Global frontrunner CD47 antibody, potentially 1st CD47 product in China
- HemeOnc & solid tumors
- Phase 2

Uliledlimab *TJD5*

- Global frontrunner CD73 antibody and potentially 1st CD73 antibody in China
- Solid tumors
- Phase 2

Plonmarlimab *TJM2*

- The only clinical-stage GM-CSF antibody in China
- CRS-COVID-19
- Phase 3

Efineptakin Alfa *TJ107*

- The only clinical-stage long-acting recombinant human interleukin-7
- GBM & solid tumors
- Phase 2

Enoblituzumab *TJ271*

- The only clinical-stage B7-H3 antibody in China
- Solid tumors
- Phase 2

Core Asset: Felzartamab

Felzartamab TJ202

- Differentiated CD38 in China
- Multiple myeloma (multiple lines)
- Phase 3



Felzartamab (TJ202/MOR202) is an investigational human monoclonal antibody derived from MorphoSys' HuCAL® antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body's immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement dependent cytotoxicity, or CDC, an additional immune mechanism involved in tumor cell killing. Scientific research suggests that an anti-CD38 antibody may have therapeutic potential also in other cancers as well as autoimmune diseases. Based on a licensing agreement between MorphoSys and I-Mab signed in November 2017, I-Mab owns the exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao.

Core Asset: Felzartamab

On-going | Planned | Completed

Phase 3/Pre-BLA Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Felzartamab TJ202 *Differentiated CD38 antibody*	Greater China	3L MM	Topline data met the primary & secondary endpoints				*BLA package ready for submission*
		2L MM	Combo with Lenalidomide. Patient enrollment completed				*BLA in 2023*
		1L MM exploratory	New combo				*IND in Q1 2022*
		SLE	IND approved				*Trial to be initiated in Q1 2022*

Topline data met primary & secondary endpoints and confirmed the clinical advantages of felzartamab

- Lower injection reaction rate
- Shorter infusion time Out-patient use

Integrated commercial team to focus on launch readiness of felzartamab

- Preparing the organization
- Preparing the market
- Preparing the product

Core Asset: Eftansomatropin Alfa

Eftansomatropin Alfa TJ101

- Differentiated long-acting growth hormone in China
- Pediatric growth hormone deficiency
- Phase 3

Eftansomatropin alfa (TJ101) is a potential highly differentiated long-acting recombinant human growth hormone being developed as a more convenient and effective therapy for growth hormone deficiency (GHD). Like endogenous growth hormone, eftansomatropin alfa stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth. IGF-1 is a reliable pharmacodynamic marker and the key mediator of growth-promoting activity of eftansomatropin alfa. Eftansomatropin alfa is based on Genexine's patented hyFc® technology. The hyFc part consists of a portion of human immunoglobulin D ("IgD") and G4 ("IgG4"). The former contains a flexible hinge, and the latter is responsible for half-life extension through neonatal Fc receptor ("FcRn")-mediated recycling.

Core Asset: Eftansomatropin Alfa

On-going | Planned | Completed

Phase 3/Pre-BLA Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Eftansomatropin Alfa TJ101 *Long-acting growth hormone*	China	PGHD	On track to complete patient enrollment in 2022				*BLA in 2023*

Advanced Technology

- Natural long-acting GH protein
- Proven hyFc long-acting technology
- No PEG or chemical linkers, potentially safer for long term usage

Excellent Efficacy & Safety

- Efficacy and safety validated in a phase 2 clinical trial[1]



Weekly VS Daily

- Weekly & biweekly sc. injections
- Improved patient compliance
- Auto-Injector under development

Development Timeline

Phase 3 in 165 PGHD patients, 12-month observation time

BLA expected in 2023

1. The tolerability of TJ101 was consistent with known properties of marketed products

Core Asset: Lemzoparlimab

Lemzoparlimab TJC4

- Global frontrunner CD47 monoclonal antibody, Potentially the first CD47 product in China
- HemeOnc & solid tumors
- Phase 2, potentially advancing to registrational trial



CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a “don’t eat me” signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab have discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

Core Asset: Lemzoparlimab

On-going | Planned | Completed

Core Asset Partnered with AbbVie	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Lemzoparlimab TJC4 *Highly differentiated CD47 antibody*	U.S.	NHL I-Mab/AbbVie	Combo with rituximab		57% CR, 71% ORR & 100% DCR in r/r NHL (n=7)		*Data Presented at ASH 2021*
		AML/MDS AbbVie	Including combo with AZA + Ven				
		MM AbbVie	Including combo with CD38 antibody				
		Solid Tumors I-Mab/AbbVie	Combo with pembrolizumab				*Preliminary results in 2022*
	Greater China I-Mab	NHL	Combo with rituximab				*Potentially leading to a registrational trial in 2022*
		MDS/AML	Combo with AZA				*Potentially leading to a registrational trial in 2022*
		Solid Tumors	Combo with toripalimab				*On track*

Core Asset: Ulilediimab

Ulilediimab TJD5

- Global frontrunner CD73 antibody most advanced in China
- Solid tumors
- Phase 2



Ulilediimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Ulilediimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Ulilediimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Core Asset: Uliledlimab

On-going | Planned | Completed

Core Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Uliledlimab TJD5 *Highly differentiated CD73 antibody*	U.S.	Solid Tumors	Combo with atezolizumab				
			Combo with atezolizumab in selected solid tumors				*On track*
	Greater China	Solid Tumors	Combo with toripalimab in selected solid tumors				*Preliminary results in 2022*
			New combo				*IND planned*

Clinical response is correlated with higher co-expression of CD73 and PD-L1



- RP2D determined
- Positive efficacy signals
- Safe and well tolerated
- Potential correlation with CD73 as a biomarker

Global partnering deal pending

Exploring a potential global partnering deal where I-Mab expects to retain the Greater China rights

Core Asset: Plonmarlimab

Plonmarlimab TJM2

- The only clinical-stage GM-CSF antibody in China
- CRS-COVID-19
- Phase 2

Plonmarlimab (or TJM2) is an internally discovered neutralizing antibody against human GM-CSF, an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as RA GM-CSF can polarize macrophages into the pro-inflammatory M1 phenotype and is known to induce an inflammatory cascade involving other pro-inflammatory cytokines such as tumor-necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-12, and IL-23. It is evident that GM-CSF plays a crucial role in the pathogenesis and disease progression of multiple autoimmune conditions.

Plonmarlimab specifically binds to human GM-CSF with high affinity and can block GM-CSF from binding to its receptor, thereby preventing downstream signalling and target cell activation. As a result, it can effectively inhibit inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage.

Core Asset: Plonmarlimab

On-going | Planned | Completed

Core Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3 /Registrational	Expected Milestone
Plonmarlimab TJM2 *GM-CSF antibody*	U.S.	CRS COVID-19	Interim data met primary and secondary endpoints				*Continuing the Ph 2/3 clinical study in the U.S.*
	Greater China	CRS Others	Exploring other CRS conditions				*IND planned*

Ph2/3 Interim data met primary and secondary endpoints

CRS-COVID-19	Plonmarlimab	Placebo
MVF rate at Day 30	84%	77%
Mortality rate by Day 30	5%	13%

Continuing the Ph 2/3 study

Biomarker Results Consistent with Clinical Outcome

TARC, IP10, GCSF, IL10, IL6, MCP1, IL1RA, TNF-α

Decreased

Clinical Improvements Comparable to Lenzilumab[1]

CRS-COVID-19	Lenzilumab	Placebo
MVF rate at Day 28	84%	78%
Mortality rate by Day 28	10%	14%

1. Source: www.medrxiv.org/content/10.1101/2021.05.01.21256470v1.full.pdf

Core Asset: Efineptakin Alfa

Efineptakin Alfa TJ107

- The only clinical-stage long-acting recombinant human interleukin-7
- GBM & solid tumors
- Phase 2

Efineptakin alfa, also known as TJ107/GX-I7/NT-I7, is the world's first and only long-acting recombinant human interleukin-7 (rhIL-7), known to boost T lymphocytes by increasing their number and functions. It emerged from Genexine's proprietary hyFc® platform for the discovering of long-acting biologics. I-Mab has acquired exclusive rights from Genexine to develop and commercialize efineptakin alfa in Greater China. Efineptakin alfa may have utility in cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, for which there is no approved treatment. Efineptakin alfa has also been shown to synergize with a PD-1 antibody in various tumor animal models potentially through increased T-lymphocyte activation and proliferation.

Core Asset: Efineptakin Alfa

On-going | Planned | Completed

Core Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Efineptakin Alfa TJ107 *Novel long-acting IL-7*	Greater China	Solid Tumors	Completed a Ph 1 clinical trial in China				
		GBM	Ph 2 clinical trial on track				*On track*
		TNBC & HNC	Combo with pembrolizumab in Ph 2 trial				*On track*

Differentiated Product with Huge Market Potential

The world's first and only long-acting recombinant human IL-7 being developed as:

1. A monotherapy for the treatment of cancer patients with **lymphopenia** and
2. **Combo immunotherapy** with PD-1/PD-L1 antibody for cancers

Excellent Clinical Data Published by Our Partners

GBM	ALC increased by **1.3 – 4.1 fold** and a one-year survival rate of **83.3%** being observed so far
TNBC	Combo with pembrolizumab showed an **ORR of 28%** in patients with metastatic TNBC, higher than pembrolizumab monotherapy

Core Asset: Enoblituzumab

Enoblituzumab TJ271

- The only clinical-stage B7-H3 antibody in China
- Solid tumors
- Phase 2



Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins. B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer. Enoblituzumab has been or is currently being evaluated in clinical trials as a monotherapy or in combination with anti-PD-1-based therapies in patients with B7-H3-expressing cancers. I-Mab Biopharma acquired the development and commercial rights from MacroGenics for Greater China.

Core Asset: Enoblituzumab

On-going | Planned | Completed

Core Asset	Commercial Rights	Indications	Preclinical	Phase 1	Phase 2	Phase 3/ Registrational	Expected Milestone
Enoblituzumab TJ271 *Novel B7-H3 antibody*	Greater China	Solid Tumors	Combo with PD-1				*Ph2 "basket trial" ongoing*

Engagement of both innate and adaptive immunity as mediators of its anti-tumor activity



Clinical Data Published by Our Partners show Enobituzumab is well tolerated & results in anti-tumor activity observed

SCCHN	Combination with pembrolizumab in treatment of SCCHN showed **ORR of 33.3%**
NSCLC	**ORR is 35.7%** in NSCLC patients who are PD-L1 negative (i.e. <1%)

Value Creation through Global Collaborations

Cash Flow From Partnering Deals ~USD 1 Billion by 2025

Collaboration

abbvie

WuXi Biologics
Global Solution Provider

KALBE

AFFINITY 亲合力

COMPLIX
AlphabodyTherapeutics

嘉晨西海 immorna

国药控股 SINOPHARM

neoX BIOTECH

In-licensing

FERRING PHARMACEUTICALS

morphosys

Genexine

MACROGENICS

Co-development

ablbio
medicine for a better life

Roche

Novamab 洛启生物

MSD

君实生物 TopAlliance

Out-licensing

abbvie

JUMPCAN 济川药业

CSPC 石药集团

ablbio
medicine for a better life

乐普医疗 LEPU MEDICAL

Global Strategic Partnership with AbbVie

AbbVie obtains Ex-Greater China rights to develop and commercialize lemzoparlimab; I-Mab retains Greater China rights

Total aggregate value under the agreement
> US$1.94bn + US$1bn *

One of the Largest Out-license Deals in Biotech Sector

US$180m upfront + **US$20m** immediate milestone payment	**US$1.74bn** in additional milestones with **sales royalties**	**≥ US$1.0bn** option for upfront and milestone payments on BsAbs

2020 Deal of the Year
BioCentury and BayHelix

Note: AbbVie has a right of first negotiation to in-license further development and commercialization of two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by I-Mab. The potential value of each such license is a minimum of US$500 million in upfront and milestone payments, for a combined total of no less than US$1 billion.

Commercial Partnership with Jumpcan

$315M

+

Royalties / Shared Profits

JUMPCAN 济川药业

Leading Player in Pediatric Medicine

One of the Largest Partnering Deals in China Biotech Industry to Date

Bringing together the strengths of a global biotech & a China leading pharma
I-Mab's leadership in **innovation** & Jumpcan's leadership in **pediatrics**
Accelerating the commercialization of eftansomatropin alfa

$315M upfront and milestone + royalties / shared profits
$35M upfront & **$280M** upon development, registration, and sales milestone achievements
Share profits on a **50/50** basis, I-Mab is entitled to receive tiered **low double-digit** royalties on net sales of product

Another milestone for I-Mab's transformation towards commercialization
I-Mab will continue to lead the phase 3 trial of eftansomatropin alfa in PGHD
I-Mab will be the **MAH** of the product and lead BLA submission to NMPA

Transformation Towards a Fully Integrated Global Biopharma

I-Mab Hangzhou: GMP Manufacturing Provider

Process Development & Analytical Laboratories, Pilot Plant in Operation

4,000m² state-of-the-art process and analytical development lab established and in execution for IND stage upstream and downstream process development, scale-up and biologics analytical method development

- Three 2,000L scale biologics manufacturing lines to be qualified in June 2022 with a capacity of 60 drug substance batches per year
- Drug product filling and lyophilization line to be qualified in Q3 2022 with a capacity of 0.7 million vials per year

Pilot Capacity

2x2,000L and 1x2,000L, mid-2022

Commercial Capacity

Up to 8x4,000L, 2024

Commercial Capacity under Construction

- Establish GMP operations and quality systems fully compliant with standards and requirements of NMPA, FDA, and EMA
- Phase I construction with 80,000 m² manufacturing floor space completed in Dec 2021; facility and process design and purchasing of key/critical equipment to be completed in 2022, and GMP ready to be expected in 2024
- 8x4,000L lines to be established with a capacity of 120 drug substance batches per year (including TJC4, TJD5, TJ202, TJ101)
- Drug product capacity of 5M vials to be established

Commercial Strategy: HemeOnc Portfolio

Covering 3 major disease groups
Striving for potential best 2L and 1L treatment options[1]



Lemzoparlimab
Leukemia (AML/MDS)
1L *combo – AZA + Ven*
2L *combo – AZA*

Lemzoparlimab
Lymphoma (NHL)
1L *new combo*
2L *combo – Rituximab*

Felzartamab
Multiple Myeloma
1L *new combo (trial planned)*
2L *combo – Lenalidomide*
3L *monotherapy*

1. Including planned novel combos

Commercialization Capabilities

Core Commercialization Capabilities

Mr. Yifei Zhu
Chief Commercial Officer

Core commercial teams in place

- **Market access, Medical Affairs and Marketing:** gearing up for product launch
- **Medical Affairs and Marketing:** increasing KOL engagement to build brand awareness

Lishui GSP Entity

- Under construction

Data System in Place

- Supply chain
- CRM, etc.

Accelerating Commercialization through Strategic Partnerships

October 2021
Strategic partnership with **Sinopharm**

November 2021
Partnering deal with **Jumpcan**

November 2021
Strategic partnership with **Institute of Hematology & Blood Diseases Hospital**

Talents and Senior Management Team

Diverse, Talented and Experienced Global Team

R&D
65%

Ph.D. Master's
58%

Female
67%

Global Experience
66%

I-Mab China team


I-Mab U.S. team

Scientific Advisory Board

Senior Management with a Proven Track Record of Success

John Long, MBA, CFA
Chief Financial Officer

- 20+ years of experiences in financial management, strategic planning, fundraising and capital market transactions
- Served as CFO or SVP at the WuXi AppTec Group, WuXi NextCODE Genomics, Genecast Biotechnology, and StemiRNA Therapeutics
- MBA, Wharton School of the University of Pennsylvania
- B.S., University of International Business and Economics in Beijing

药明康德 WuXi PharmaTech · WuXiNextCODE · Wharton University of Pennsylvania · StemiRNA 斯微生物

Andrew Zhu, M.D., Ph.D
President

M.D., Peking University Health Science Center
Ph.D., Columbia University

- Former Professor of Medicine at Harvard Medical School, Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center, CSO of Jiahui Health and Director of Jiahui International Cancer Center
- Led or participated in 50+ global oncology clinical trials
- Published 300+ papers in scientific journals
- Clinical residency, Yale New Heaven Hospital, Memorial Sloan-Kettering Cancer Center

HARVARD MEDICAL SCHOOL · MASSACHUSETTS GENERAL HOSPITAL · JIAHUI HEALTH 嘉会医疗

Jingwu Zang, M.D., Ph.D
Founder, Chairman, Acting CEO

M.D., Shanghai Jiaotong University
Ph.D., University of Brussels
Post-doc, Harvard Medical School
Clinical residency, Baylor College of Medicine
US-licensed physician

- >10 years of pharma R&D executive positions
- CSO and President of Simcere Pharmaceuticals
- SVP, Head, Neuroscience therapeutic Area, GSK
- Professor at Baylor College of Medicine
- Professor & founding directors of IHS and IPS in Chinese Academy of Sciences
- Published over 160 papers in scientific journals

HARVARD MEDICAL SCHOOL · 中国科学院 · Baylor College of Medicine · gsk · 先声药业 Simcere

Zheru Zhang, Ph.D
President

- 20+ years of experience in CMC and quality management in pharma industry in US, Korea and China
- Previously served management roles at BMS, J&J and Celltrion
- Led or participated in 20 biologics IND and six global BLA submissions
- Ph.D., University of Alberta

Johnson & Johnson · Bristol Myers Squibb · HEALTHCARE CELLTRION

Yifei Zhu
Chief Commercial Officer

- More than two decade's commercialization experience at global and domestic pharma and biotech companies
- Served as Vice President and General Manager of the sales division of Qilu pharmaceutical group, also held various senior management positions at BeiGene and Xi'an Janssen
- Building commercial teams and leading successful product launches at domestic and international pharma companies.

Johnson & Johnson · BeiGene · 齐鲁制药 QILU PHARMACEUTICAL

Taylor Guo, Chief Science Officer · Thomas Song, Compliance Head · Claire Xu, U.S. Site Head · Weimin Tang, Chief Business Officer · Gigi Feng, Chief Comms. Officer · Jielun Zhu, Chief Strategy Officer · John Long, Chief Finance Officer · Andrew Zhu, President · Jingwu Zang, Founder, Chairman and Acting CEO · Zheru Zhang, President · Yifei Zhu, Chief Commercial Officer · Isaac Meng, SVP, Medical Office · Min Yin, VP, Operations · Richard Li, Chief Legal Officer · Gracie Hao, HR Head · Neil Warma, U.S. GM · Tianyi Zhang, VP, Investor Relations

Global Footprint, Global Capital Markets

Corporate Responsibilities

Global Footprint

Global Headquarters @Shanghai

Research Laboratories

Global Capital Market Listings

Accelerating dual listing process for HKEX to provide flexibility and an alternative channel for investors

Environmental, Social and Governance (ESG)

Set up ESG Committee

Supervising the ESG strategies, policies, long-term sustainability objectives and risks of the Company

BBB Rating by the MSCI ESG assessment

The highest newly initiated rating among China-based biotech companies

Corporate Responsibilities

Patients

Develop novel products in Immuno-oncology, with the mission to bring transformational medicines to patients through innovation.

People

Create a diverse and inclusive culture by promoting gender equity, and supporting employees' personal and career development

Philanthropy

During COVID-19 outbreak in 2020, I-Mab donated medical supplies worth of RMB 800,000 to hospitals and healthcare workers in Wuhan, China and US$ 50,000 to BayHelix.

In July 2021, I-Mab donated RMB 1 million to Henan Charity General Federation for the rescue and reconstruction of flood-hit regions in Henan Province.

Awards and Recognition

2021 Entrepreneur of the Year
EY

Executive of the Year
Scrip Awards

mpany of the Year
eal of the Year
ry, BayHelix

Excellent Employer
T+Employer™

2021 Leading DEI X Inclusion Award
sHero

ompa
ional In



50 Smartest Companies
MIT Technology Review

p 10 China Biotech
FiercePharma

2020 China H re
New Power Top 10
people.cn

2021 Top 50 Enterprises of Technology Power
Tech Power

2020 Best Value Healthcare Companies
Sina.com

Top 10 Immuno-Oncology Startups of 2019
GEN

Other Awards

CCS Top 50 Companies
Barron's, Caijing and Tiger Securities

Top 10 New IPO
The Hong Kong Institute of Chartered Secretaries

Top 50 Listed Company Leaders
Global Founders Summit

Best Overseas IPO Award
PharmaDJ

Innovation Top 100
E-Healthcare Executive

2020 Future Stars
Shanghai United Media Group



Bring Transformational Medicines to Patients through Innovation

I-MAB BIOPHARMA

@i-mab

@i-mab